Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Buggisch

Showing results (51-60 of 110) with videos related to

Pageof 11
Sort By:
Hepatology (Baltimore, Md.)|July 4, 2009
Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1-infected patientsThomas Berg, Viola Weich, Gerlinde Teuber, et al.
Journal of Hepatology|November 15, 2017
Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in chronic hepatitis CPeter Buggisch, Johannes Vermehren, Stefan Mauss, et al.
Hepatology (Baltimore, Md.)|December 28, 2016
Eight weeks of ledipasvir/sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infectionKris V Kowdley, Vinay Sundaram, Christie Y Jeon, et al.
Journal of Hepatology|November 1, 2011
Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: an international multicenter cohort studyJorg Petersen, Vlad Ratziu, Maria Buti, et al.
BMC Gastroenterology|October 8, 2011
The transhepatic endotoxin gradient is present despite liver cirrhosis and is attenuated after transjugular portosystemic shunt (TIPS)Daniel Benten, Julian Schulze zur Wiesch, Karsten Sydow, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|March 25, 2015
Improved pharmacodynamics and pharmacokinetics after i.v. application of peginterferon alfa-2a in hepatitis C null respondersBalazs Fülöp, Michael Biermer, Markus Cornberg, et al.
Plos One|July 19, 2016
An Open-Label Trial of 12-Week Simeprevir plus Peginterferon/Ribavirin (PR) in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 1 (GT1)Tarik Asselah, Christophe Moreno, Christoph Sarrazin, et al.
European Journal of Gastroenterology & Hepatology|October 8, 2019
Hepatitis C therapy with direct antiviral agents in patients with advanced chronic kidney disease: real-world experience of the German Hepatitis C-Registry (Deutsches Hepatitis C-Register)Johannes Wiegand, Peter Buggisch, Stefan Mauss, et al.
Journal of Viral Hepatitis|October 14, 2018
Estimation of liver fibrosis by noncommercial serum markers in comparison with transient elastography in patients with chronic hepatitis C virus infection receiving direct-acting antiviral treatmentViola Knop, Wolf P Hofmann, Peter Buggisch, et al.
Journal of Hepatology|July 23, 2008
Evaluation of complement factor 5 variants as genetic risk factors for the development of advanced fibrosis in chronic hepatitis C infectionJuliane Halangk, Christoph Sarrazin, Konrad Neumann, et al.
Pageof 11

Showing results (51-60 of 110) with videos related to

Sort By:
Pageof 11
Hepatology (Baltimore, Md.)|July 4, 2009
Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1-infected patientsThomas Berg, Viola Weich, Gerlinde Teuber, et al.
Journal of Hepatology|November 15, 2017
Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in chronic hepatitis CPeter Buggisch, Johannes Vermehren, Stefan Mauss, et al.
Hepatology (Baltimore, Md.)|December 28, 2016
Eight weeks of ledipasvir/sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infectionKris V Kowdley, Vinay Sundaram, Christie Y Jeon, et al.
Journal of Hepatology|November 1, 2011
Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: an international multicenter cohort studyJorg Petersen, Vlad Ratziu, Maria Buti, et al.
BMC Gastroenterology|October 8, 2011
The transhepatic endotoxin gradient is present despite liver cirrhosis and is attenuated after transjugular portosystemic shunt (TIPS)Daniel Benten, Julian Schulze zur Wiesch, Karsten Sydow, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|March 25, 2015
Improved pharmacodynamics and pharmacokinetics after i.v. application of peginterferon alfa-2a in hepatitis C null respondersBalazs Fülöp, Michael Biermer, Markus Cornberg, et al.
Plos One|July 19, 2016
An Open-Label Trial of 12-Week Simeprevir plus Peginterferon/Ribavirin (PR) in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 1 (GT1)Tarik Asselah, Christophe Moreno, Christoph Sarrazin, et al.
European Journal of Gastroenterology & Hepatology|October 8, 2019
Hepatitis C therapy with direct antiviral agents in patients with advanced chronic kidney disease: real-world experience of the German Hepatitis C-Registry (Deutsches Hepatitis C-Register)Johannes Wiegand, Peter Buggisch, Stefan Mauss, et al.
Journal of Viral Hepatitis|October 14, 2018
Estimation of liver fibrosis by noncommercial serum markers in comparison with transient elastography in patients with chronic hepatitis C virus infection receiving direct-acting antiviral treatmentViola Knop, Wolf P Hofmann, Peter Buggisch, et al.
Journal of Hepatology|July 23, 2008
Evaluation of complement factor 5 variants as genetic risk factors for the development of advanced fibrosis in chronic hepatitis C infectionJuliane Halangk, Christoph Sarrazin, Konrad Neumann, et al.
Pageof 11